GeraldFCoxMDGerald F. Cox, MD, PhD

Summary

• I am a board-certified clinical geneticist who has been developing drugs to treat rare genetic diseases for over 20 years. Most of my industry experience was in clinical development at Genzyme, where I contributed to the approvals of several drugs for lysosomal storage disorders, including Gaucher and Pompe diseases, and MPS I and MPS II. From 2016-2018, I was CMO at Editas Medicine, where I led the first IND for a CRISPR medicine delivered in vivo to treat a form of genetic blindness (LCA10). For the past two years, I have been consulting for several biotech companies developing innovative drugs for rare genetic diseases with therapeutic approaches that span all the way from small molecules to enzymes, proteins, antibodies, gene therapy, and genmoe editing. I serve on the Board of Directors for the National Tay-Says and Allied Diseases organization, where I have been helping families understand the clinical trial process and how they can contribute to researching treatments and cures. Throughout my career, I have always maintained a continuity clinic in clinical Genetics at Boston Children's Hospital - some of the infants with formerly fatal diseases are now all grown up and entering their 30's.